United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
578.54
+0.91 (0.16%)
At close: Apr 14, 2026, 4:00 PM EDT
579.54
+1.00 (0.17%)
After-hours: Apr 14, 2026, 6:39 PM EDT
United Therapeutics Employees
United Therapeutics had 1,400 employees as of December 31, 2025. The number of employees increased by 95 or 7.28% compared to the previous year.
Employees
1,400
Change (1Y)
95
Growth (1Y)
7.28%
Revenue / Employee
$2,273,357
Profits / Employee
$953,357
Market Cap
25.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,400 | 95 | 7.28% |
| Dec 31, 2024 | 1,305 | 137 | 11.73% |
| Dec 31, 2023 | 1,168 | 183 | 18.58% |
| Dec 31, 2022 | 985 | 20 | 2.07% |
| Dec 31, 2021 | 965 | 15 | 1.58% |
| Dec 31, 2020 | 950 | 30 | 3.26% |
| Dec 31, 2019 | 920 | 60 | 6.98% |
| Dec 31, 2018 | 860 | 60 | 7.50% |
| Dec 31, 2017 | 800 | 50 | 6.67% |
| Dec 31, 2016 | 750 | 0 | - |
| Dec 31, 2015 | 750 | 10 | 1.35% |
| Dec 31, 2014 | 740 | 34 | 4.82% |
| Dec 31, 2013 | 706 | 83 | 13.32% |
| Dec 31, 2012 | 623 | 80 | 14.73% |
| Dec 31, 2011 | 543 | 23 | 4.42% |
| Dec 31, 2010 | 520 | 110 | 26.83% |
| Dec 31, 2009 | 410 | 50 | 13.89% |
| Dec 31, 2008 | 360 | 40 | 12.50% |
| Dec 31, 2007 | 320 | 35 | 12.28% |
| Dec 31, 2006 | 285 | 75 | 35.71% |
| Dec 31, 2005 | 210 | 40 | 23.53% |
| Dec 31, 2004 | 170 | 10 | 6.25% |
| Dec 31, 2003 | 160 | 10 | 6.67% |
| Dec 31, 2002 | 150 | 22 | 17.19% |
| Dec 31, 2001 | 128 | 18 | 16.36% |
| Dec 31, 2000 | 110 | 47 | 74.60% |
| Dec 31, 1999 | 63 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 30,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,535 |
| Zoetis | 14,500 |
| Elanco Animal Health | 9,900 |
| Alkermes | 2,050 |
UTHR News
- 6 days ago - United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure - Business Wire
- 15 days ago - United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2 - Business Wire
- 4 weeks ago - United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine - Business Wire
- 5 weeks ago - United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program - Business Wire
- 6 weeks ago - United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference - Business Wire
- 6 weeks ago - United Therapeutics' blood pressure drug meets main, secondary goals in late-stage study - Reuters
- 6 weeks ago - United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - Business Wire
- 6 weeks ago - These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings - Benzinga